Shares of InterMune (ITMN-5.7%) tumble despite strong Q1 earnings and sales after the biotech company says it isn’t in talks on a sale. Bloomberg reported yesterday that the company with an approved drug for a rare lung disease was working with Goldman Sachs to find a buyer.